Metagenomi Therapeutics (MGX) Current Deferred Revenue (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Current Deferred Revenue data on file, last reported at $9.3 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $9.3 million, down 63.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.3 million (down 63.51% YoY), and the FY2025 annual result was $8.7 million, down 61.78% from the prior year.
• Current Deferred Revenue rose to $9.3 million in Q1 2026 per MGX's latest filing, from $8.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $48.3 million in Q1 2024 and troughed at $8.7 million in Q4 2025.
• A 4-year average of $25.7 million and a median of $24.1 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue plunged 42.56% in 2025, then plunged 63.51% in 2026.
• A 4-year view of Current Deferred Revenue shows it stood at $48.1 million in 2023, then sank by 52.65% to $22.8 million in 2024, then sank by 61.78% to $8.7 million in 2025, then increased by 6.97% to $9.3 million in 2026.
• Business Quant data shows MGX's Current Deferred Revenue at $9.3 million in Q1 2026, $8.7 million in Q4 2025, and $12.9 million in Q3 2025.